Characterization of Clinical and Genetic Risk Factors Associated with Dyslipidemia after Kidney Transplantation

Table 2

Comparison of pharmacokinetic parameters (TAC, MMF, and steroid) between patients with and without dyslipidemia.

Drug	Parameters	After one month
		With dyslipidemia	Without dyslipidemia
TAC	Dose/BW (mg/kg/day)	0.17 ± 0.08	0.20 ± 0.10	0.679
	(ng·hr/mL)	170.0 ± 34.6	187.4 ± 46.3	0.457
	(ng/mL)	18.6 ± 4.7	21.1 ± 6.7	0.166
	Trough	9.2 ± 3.2	9.9 ± 3.3	0.518
MMF	Dose/BW (mg/kg/day)	25.9 ± 7.1	22.3 ± 6.9	0.012
	(ng·hr/mL)	46.0 ± 26.8	46.2 ± 18.7	0.611
	(ng/mL)	9.3 ± 5.5	9.0 ± 4.9	0.716
	Trough	3.9 ± 2.3	2.8 ± 1.7	0.192
Steroid	Dose/BW (mg/kg/day)	0.20 ± 0.05	0.19 ± 0.03	0.023
	(ng·hr/mL)	1051.1 ± 426.9	1059.1 ± 407.4	0.936
	(ng/mL)	130.9 ± 45.9	141.3 ± 46.5	0.375
	Trough	0.9 ± 2.6	2.4 ± 8.5	0.549

Mann-Whitney tests were employed to analyze continuous values between groups.
values less than 0.05 were considered to be statistically significant.
Values are expressed as mean ± SD.
TAC, tacrolimus; MMF, mycophenolate mofetil; BW, body weight; AUC, area under the concentration-time curve; , maximal concentration.